StockNews.AI
HAE
StockNews.AI
169 days

Haemonetics Announces Executive Leadership Updates

1. Frank Chan appointed as COO, effective April 7, 2025. 2. Roy Galvin promoted to Chief Commercial Officer immediately. 3. Chan brings 25 years of experience in healthcare technology. 4. Galvin expands responsibilities for global hospital and plasma business. 5. Leadership changes aim to drive growth and innovation at Haemonetics.

6m saved
Insight
Article

FAQ

Why Bullish?

The positive changes in leadership enhance strategic direction and operational excellence, suggesting future growth. Past examples indicate strong leadership transitions have historically driven stock performance positively in medical technology.

How important is it?

The article highlights crucial leadership appointments that may significantly influence future company direction and market performance, marking the importance of the news.

Why Long Term?

Leadership changes typically take time to manifest in stock performance, reflecting a long-term growth strategy. For instance, transitions at other companies often took several quarters to reflect in financial results.

Related Companies

MDTJNJCOV
Frank Chan joins Haemonetics as Executive Vice President, Chief Operating Officer; Roy Galvin named Executive Vice President, Chief Commercial Officer , /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced updates to its Executive Leadership team. Frank Chan, Ph.D. will join Haemonetics as Executive Vice President, Chief Operating Officer on April 7, 2025, and Roy Galvin has been appointed as the company's Executive Vice President, Chief Commercial Officer effective immediately. As Chief Operating Officer, Chan will direct Haemonetics' research and development as well as regulatory affairs, driving innovation and operational excellence to support the company's growth. He will also oversee Haemonetics' global manufacturing and supply chain operations. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer. With more than 25 years of experience in medical device and healthcare technology leadership, Chan has successfully delivered innovative solutions to market, expanded patient access with global market development, and led business transformation initiatives across large organizations. He joins Haemonetics from Medtronic plc, where he served as President of Acute Care & Monitoring, overseeing a global portfolio of airway management, patient monitoring, and connected care solutions. Prior to Medtronic, he held roles of increasing responsibility at Covidien plc (acquired by Medtronic) and DePuy Orthapaedics, Inc. (a Johnson & Johnson company). Galvin joined Haemonetics in 2022 as President, Global Plasma and Blood Center. As Chief Commercial Officer, he will now have responsibility for the company's Global Hospital business as well as Global Plasma and Blood Center, directing all commercialization initiatives to expand the reach and breadth of Haemonetics' full product portfolio. Galvin brings to the role extensive experience in the global healthcare technology field for hospitals and the surgical suite, with over 25 years working at Medtronic plc scaling businesses in the Neuroscience and Orthopedic markets. "We are executing our long-range plan to achieve exciting growth and build a foundation for sustained success. By strengthening our executive leadership with the addition of Frank Chan and an expanded role for Roy Galvin, we are well-positioned to drive the next phase of our growth," said Chris Simon. About Haemonetics Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com. Investor Contacts: Olga Guyette, Vice President-Investor Relations & Treasury Investor Relations David Trenk, Manager-Investor Relations (781) 356-9763 (203) 733-4987 [email protected]   [email protected] Media Contact: Josh Gitelson, Senior Director-Global Communications (781) 356-9776 [email protected]  SOURCE Haemonetics Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News